首页 > 最新文献

Swiss medical weekly最新文献

英文 中文
Supplementum 284: Abstracts of the 56th Annual meeting of the Swiss Society of Nephrology. 补编 284:瑞士肾脏病学会第 56 届年会摘要。
IF 2.1 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-22 DOI: 10.57187/s.4290
Swiss Society Of Nephrology
{"title":"Supplementum 284: Abstracts of the 56th Annual meeting of the Swiss Society of Nephrology.","authors":"Swiss Society Of Nephrology","doi":"10.57187/s.4290","DOIUrl":"https://doi.org/10.57187/s.4290","url":null,"abstract":"","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"154 ","pages":"4290"},"PeriodicalIF":2.1,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of oral immunotherapy for cashew nut and peanut allergy in children - a retrospective single-centre study. 腰果和花生过敏儿童口服免疫疗法的安全性--一项回顾性单中心研究。
IF 2.1 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-20 DOI: 10.57187/s.3691
Maria Breiding, Maarja Soomann, Michèle Roth, Johannes Trück, Felicitas Bellutti Enders

Aim of the study: Oral immunotherapy (OIT) is increasingly used for the treatment of childhood food allergies, with limited data available on cashew nut OIT. This real-life study investigated the safety and feasibility of cashew nut OIT, comparing it with peanut OIT, with a focus on the up-dosing process.

Methods: We analysed cashew nut (n = 24) and peanut (n = 38) OIT cases with treatment initiated between 2018 and 2022 at the University Children's Hospital Basel. All patients who commenced therapy within this time frame were enrolled without prior selection. Two different starting protocols were used. Within the up-dosing protocol, the nut intake was incrementally increased by 20-30% every 2 weeks until reaching a maintenance dose of 1 g of nut protein. After consuming the maintenance dose regularly for 18-24 months, a second oral food challenge was performed. Patients who passed this challenge were considered desensitised. The safety of the therapy was evaluated based on the severity of adverse reactions during the up-dosing phase. Symptom severity was evaluated using the validated ordinal food allergy severity scale (o-FASS-5).

Results: Over the study period, 33% of cashew nut-allergic and 63% of peanut-allergic patients experienced mild to moderate allergic reactions. Severe allergic reactions occurred in five peanut-allergic children with high baseline allergen-specific IgE levels. Six patients with peanut, and none with cashew nut OIT, discontinued the therapy due to adverse reactions. The mean duration to reach the maintenance phase was longer for children with asthma or another food allergy. Among children who already underwent the second oral food challenge, desensitisation was achieved in 91% (11 out of 12) of cashew nut- and 73% (11 out of 15) of peanut-allergic patients.

Conclusion: Cashew nut OIT had a low severity of adverse reactions and was generally well-tolerated. However, patient characteristics influenced side effect risk and treatment duration, emphasising the need for individualised OIT strategies.

研究目的口服免疫疗法(OIT)越来越多地用于治疗儿童食物过敏,但有关腰果 OIT 的数据却很有限。这项现实生活研究调查了腰果口服免疫疗法的安全性和可行性,并将其与花生口服免疫疗法进行了比较,重点是上量过程:我们分析了2018年至2022年期间在巴塞尔大学儿童医院开始治疗的腰果(24例)和花生(38例)OIT病例。所有在此期间开始治疗的患者均未经过事先筛选而被纳入。采用了两种不同的起始方案。在增加剂量方案中,坚果摄入量每两周递增20%-30%,直至达到1克坚果蛋白的维持剂量。在定期摄入维持剂量 18-24 个月后,进行第二次口服食物挑战。通过这次挑战的患者被视为脱敏患者。根据增加剂量阶段不良反应的严重程度来评估治疗的安全性。症状严重程度采用经过验证的食物过敏严重程度序数量表(o-FASS-5)进行评估:在研究期间,33% 的腰果过敏患者和 63% 的花生过敏患者出现了轻度至中度过敏反应。基线过敏原特异性 IgE 水平较高的 5 名花生过敏儿童出现了严重过敏反应。六名花生过敏症患者因不良反应停止了治疗,没有腰果过敏症患者因不良反应停止治疗。对于患有哮喘或其他食物过敏症的儿童来说,进入维持阶段的平均时间更长。在已经接受第二次口服食物挑战的儿童中,91%的腰果过敏患者(12人中有11人)和73%的花生过敏患者(15人中有11人)实现了脱敏:腰果 OIT 的不良反应严重程度较低,一般都能很好地耐受。然而,患者的特征会影响副作用风险和治疗时间,这就强调了个体化 OIT 策略的必要性。
{"title":"Safety of oral immunotherapy for cashew nut and peanut allergy in children - a retrospective single-centre study.","authors":"Maria Breiding, Maarja Soomann, Michèle Roth, Johannes Trück, Felicitas Bellutti Enders","doi":"10.57187/s.3691","DOIUrl":"https://doi.org/10.57187/s.3691","url":null,"abstract":"<p><strong>Aim of the study: </strong>Oral immunotherapy (OIT) is increasingly used for the treatment of childhood food allergies, with limited data available on cashew nut OIT. This real-life study investigated the safety and feasibility of cashew nut OIT, comparing it with peanut OIT, with a focus on the up-dosing process.</p><p><strong>Methods: </strong>We analysed cashew nut (n = 24) and peanut (n = 38) OIT cases with treatment initiated between 2018 and 2022 at the University Children's Hospital Basel. All patients who commenced therapy within this time frame were enrolled without prior selection. Two different starting protocols were used. Within the up-dosing protocol, the nut intake was incrementally increased by 20-30% every 2 weeks until reaching a maintenance dose of 1 g of nut protein. After consuming the maintenance dose regularly for 18-24 months, a second oral food challenge was performed. Patients who passed this challenge were considered desensitised. The safety of the therapy was evaluated based on the severity of adverse reactions during the up-dosing phase. Symptom severity was evaluated using the validated ordinal food allergy severity scale (o-FASS-5).</p><p><strong>Results: </strong>Over the study period, 33% of cashew nut-allergic and 63% of peanut-allergic patients experienced mild to moderate allergic reactions. Severe allergic reactions occurred in five peanut-allergic children with high baseline allergen-specific IgE levels. Six patients with peanut, and none with cashew nut OIT, discontinued the therapy due to adverse reactions. The mean duration to reach the maintenance phase was longer for children with asthma or another food allergy. Among children who already underwent the second oral food challenge, desensitisation was achieved in 91% (11 out of 12) of cashew nut- and 73% (11 out of 15) of peanut-allergic patients.</p><p><strong>Conclusion: </strong>Cashew nut OIT had a low severity of adverse reactions and was generally well-tolerated. However, patient characteristics influenced side effect risk and treatment duration, emphasising the need for individualised OIT strategies.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"154 ","pages":"3691"},"PeriodicalIF":2.1,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142688856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac amyloidosis. 心脏淀粉样变性
IF 2.1 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-14 DOI: 10.57187/s.4186
Natallia Laptseva, Dominik C Benz, Rahel Schwotzer, Andreas J Flammer

Cardiac amyloidosis is a disease characterised by the accumulation of amyloid protein in the heart tissue. There are several types of amyloidosis, but the most common types affecting the heart are ATTR amyloidosis (caused by transthyretin protein) and AL amyloidosis (caused by abnormal immunoglobulin light chains). Cardiac amyloidosis causes typical signs and symptoms of heart failure. Diagnosis involves a combination of imaging tests such as echocardiography and cardiac magnetic resonance imaging, as well as nuclear imaging scans and tissue biopsies to confirm the presence of amyloid deposits in the heart. Treatment of cardiac amyloidosis depends on the type and severity of the disease and includes medications to manage symptoms as well as treatments targeting the underlying cause of amyloidosis. Importantly, cardiac amyloidosis is a serious condition requiring specialised care from a multidisciplinary team including cardiologists and haematologists as well as other specialists familiar with the management of this rare disease. This is crucial, as early diagnosis and treatment are important for improving outcomes.

心脏淀粉样变性是一种以淀粉样蛋白在心脏组织中积聚为特征的疾病。淀粉样变性有多种类型,但影响心脏的最常见类型是 ATTR 淀粉样变性(由转甲状腺素蛋白引起)和 AL 淀粉样变性(由异常免疫球蛋白轻链引起)。心脏淀粉样变性会导致典型的心力衰竭症状和体征。诊断需要结合超声心动图和心脏磁共振成像等影像学检查,以及核成像扫描和组织活检,以确认心脏中是否存在淀粉样蛋白沉积。心脏淀粉样变性的治疗取决于疾病的类型和严重程度,包括控制症状的药物以及针对淀粉样变性潜在病因的治疗。重要的是,心脏淀粉样变性是一种严重的疾病,需要多学科团队的专业治疗,包括心脏病专家、血液学专家以及熟悉这种罕见疾病治疗的其他专家。这一点至关重要,因为早期诊断和治疗对改善预后非常重要。
{"title":"Cardiac amyloidosis.","authors":"Natallia Laptseva, Dominik C Benz, Rahel Schwotzer, Andreas J Flammer","doi":"10.57187/s.4186","DOIUrl":"https://doi.org/10.57187/s.4186","url":null,"abstract":"<p><p>Cardiac amyloidosis is a disease characterised by the accumulation of amyloid protein in the heart tissue. There are several types of amyloidosis, but the most common types affecting the heart are ATTR amyloidosis (caused by transthyretin protein) and AL amyloidosis (caused by abnormal immunoglobulin light chains). Cardiac amyloidosis causes typical signs and symptoms of heart failure. Diagnosis involves a combination of imaging tests such as echocardiography and cardiac magnetic resonance imaging, as well as nuclear imaging scans and tissue biopsies to confirm the presence of amyloid deposits in the heart. Treatment of cardiac amyloidosis depends on the type and severity of the disease and includes medications to manage symptoms as well as treatments targeting the underlying cause of amyloidosis. Importantly, cardiac amyloidosis is a serious condition requiring specialised care from a multidisciplinary team including cardiologists and haematologists as well as other specialists familiar with the management of this rare disease. This is crucial, as early diagnosis and treatment are important for improving outcomes.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"154 ","pages":"4186"},"PeriodicalIF":2.1,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142688846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood pressure control and antihypertensive treatment in Swiss general practice: a cross-sectional study using routine data. 瑞士全科医生的血压控制和降压治疗:一项利用常规数据进行的横断面研究。
IF 2.1 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-13 DOI: 10.57187/s.3898
Stefania Di Gangi, Roman Brenner, Thomas Grischott, Jakob Martin Burgstaller, Oliver Senn, Thomas Rosemann, Stefan Markun

Aims of the study: Arterial hypertension is a major global health risk. Global surveys indicate that only half of patients with arterial hypertension receive pharmacotherapy, and only a quarter achieve the primary blood pressure target recommended by guidelines. This study aimed to evaluate the achievement of the primary blood pressure target in Swiss general practice, provide insights into arterial hypertension treatment, and identify factors associated with achieving this goal.

Methods: This cross-sectional study utilised data from a large Swiss primary care database. Patients with arterial hypertension, aged ≥18 years, who underwent blood pressure monitoring in 2021 were included. The primary observation was blood pressure control, defined as the achievement of the primary blood pressure target of systolic blood pressure <140 mm Hg and diastolic blood pressure <90 mm Hg. Demographic data from physicians and patients, blood pressure measurements, comorbidities, cardiovascular risk factors, and pharmacotherapy were collected, and arterial hypertension stages were calculated. Unadjusted and multivariable-adjusted mixed logistic regression models were used to identify factors associated with blood pressure control.

Results: A total of 49,290 patients were included, of whom 23,933 (48.6%) were female. The median patient age was 71 years (interquartile range 61-80). Blood pressure control was observed in 23,022 patients (46.7%), and 36,692 patients (74.4%) had an antihypertensive pharmacotherapy prescription. In multivariable analysis, blood pressure control was positively associated with arterial hypertension stage, antihypertensive pharmacotherapy, the intensity of blood pressure monitoring, and the number of blood pressure-increasing drugs, but negatively associated with a long-standing arterial hypertension, female sex, and old age.

Conclusions: While general practitioners appear to consider arterial hypertension stages in their treatment strategies, there is still room for improvement in arterial hypertension care by prescribing pharmacotherapy, especially in patients with long-standing arterial hypertension, female sex and old age.

研究目的动脉高血压是全球主要的健康风险。全球调查显示,只有一半的动脉高血压患者接受了药物治疗,只有四分之一的患者达到了指南推荐的初级血压目标。这项研究旨在评估瑞士全科医生实现初级血压目标的情况,提供有关动脉高血压治疗的见解,并确定实现这一目标的相关因素:这项横断面研究利用了瑞士大型初级保健数据库中的数据。研究纳入了 2021 年接受血压监测的年龄≥18 岁的动脉高血压患者。主要观察指标是血压控制情况,即达到收缩压的主要血压目标结果:共纳入 49,290 名患者,其中 23,933 名(48.6%)为女性。患者年龄中位数为 71 岁(四分位数间距为 61-80)。23,022名患者(46.7%)的血压得到了控制,36,692名患者(74.4%)拥有降压药物治疗处方。在多变量分析中,血压控制与动脉高血压分期、降压药物治疗、血压监测强度和血压升高药物的数量呈正相关,但与长期动脉高血压、女性和老年呈负相关:尽管全科医生在治疗策略中似乎会考虑动脉高血压的分期,但在动脉高血压的护理中,药物治疗处方仍有改进的余地,尤其是对长期动脉高血压、女性和老年患者。
{"title":"Blood pressure control and antihypertensive treatment in Swiss general practice: a cross-sectional study using routine data.","authors":"Stefania Di Gangi, Roman Brenner, Thomas Grischott, Jakob Martin Burgstaller, Oliver Senn, Thomas Rosemann, Stefan Markun","doi":"10.57187/s.3898","DOIUrl":"https://doi.org/10.57187/s.3898","url":null,"abstract":"<p><strong>Aims of the study: </strong>Arterial hypertension is a major global health risk. Global surveys indicate that only half of patients with arterial hypertension receive pharmacotherapy, and only a quarter achieve the primary blood pressure target recommended by guidelines. This study aimed to evaluate the achievement of the primary blood pressure target in Swiss general practice, provide insights into arterial hypertension treatment, and identify factors associated with achieving this goal.</p><p><strong>Methods: </strong>This cross-sectional study utilised data from a large Swiss primary care database. Patients with arterial hypertension, aged ≥18 years, who underwent blood pressure monitoring in 2021 were included. The primary observation was blood pressure control, defined as the achievement of the primary blood pressure target of systolic blood pressure <140 mm Hg and diastolic blood pressure <90 mm Hg. Demographic data from physicians and patients, blood pressure measurements, comorbidities, cardiovascular risk factors, and pharmacotherapy were collected, and arterial hypertension stages were calculated. Unadjusted and multivariable-adjusted mixed logistic regression models were used to identify factors associated with blood pressure control.</p><p><strong>Results: </strong>A total of 49,290 patients were included, of whom 23,933 (48.6%) were female. The median patient age was 71 years (interquartile range 61-80). Blood pressure control was observed in 23,022 patients (46.7%), and 36,692 patients (74.4%) had an antihypertensive pharmacotherapy prescription. In multivariable analysis, blood pressure control was positively associated with arterial hypertension stage, antihypertensive pharmacotherapy, the intensity of blood pressure monitoring, and the number of blood pressure-increasing drugs, but negatively associated with a long-standing arterial hypertension, female sex, and old age.</p><p><strong>Conclusions: </strong>While general practitioners appear to consider arterial hypertension stages in their treatment strategies, there is still room for improvement in arterial hypertension care by prescribing pharmacotherapy, especially in patients with long-standing arterial hypertension, female sex and old age.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"154 ","pages":"3898"},"PeriodicalIF":2.1,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142688842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the real-world management of catheter-associated urinary tract infections by Swiss general practitioners and urologists: insights from an online survey. 探索瑞士全科医生和泌尿科医生对导尿管相关性尿路感染的实际处理方法:一项在线调查的启示。
IF 2.1 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-07 DOI: 10.57187/s.3933
Iris Zünti, Emilio Arbelaez, Sarah Tschudin-Sutter, Andreas Zeller, Florian S Halbeisen, Hans-Helge Seifert, Kathrin Bausch

Aim: To assess and compare the real-world management of catheters and catheter-associated urinary tract infections (CAUTI) among Swiss general practitioners and urologists, encompassing diagnosis, treatment and prophylaxis.

Methods: An anonymised online questionnaire was distributed among Swiss general practitioners and urologists between January and October 2023 via the networks of Sentinella and the Swiss Association of Urology. The questionnaire consisted of questions on catheter management, including diagnosis, treatment and prophylaxis of CAUTI. Analysis was performed by discipline. Fisher's exact test was applied for comparisons (statistical significance with p <0.05).

Results: Out of 175 participating physicians, the majority were involved in catheter management. Urologists exhibited significantly higher levels of competence as compared to general practitioners (67.1% vs 20.9%). Although no significant differences were observed regarding diagnostic approaches between disciplines, unrecommended diagnostic methods were frequently applied. general practitioners reported that they treated non-febrile CAUTI for longer durations, while urologists indicated that they treated febrile CAUTI longer. Additionally, the use of fluoroquinolones was more prevalent among general practitioners compared to urologists, while prophylactic measures were more frequently applied by urologists.

Conclusions: Catheter and CAUTI management entail significant uncertainty for general practitioners. CAUTI management varied notably between general practitioners and urologists in terms of treatment and prophylaxis. The use of non-recommended diagnostic approaches and drugs was common. This trend, along with inappropriate diagnostic methods and prophylaxis, may increase antimicrobial resistance and CAUTI morbidity. The study emphasises the necessity for diagnostic and antimicrobial stewardship interventions, and proper training in CAUTI management for general practitioners and urologists.

目的:评估和比较瑞士全科医生和泌尿科医生对导尿管和导尿管相关尿路感染(CAUTI)的实际管理情况,包括诊断、治疗和预防:方法:2023 年 1 月至 10 月期间,通过 Sentinella 和瑞士泌尿外科协会网络向瑞士全科医生和泌尿科医生发放了一份匿名在线问卷。问卷内容包括导尿管管理问题,包括 CAUTI 的诊断、治疗和预防。分析按学科进行。采用费雪精确检验进行比较(以 p 表示统计显著性):在 175 名参与调查的医生中,大多数都参与了导管管理。泌尿科医生的能力水平明显高于全科医生(67.1% 对 20.9%)。全科医生称他们治疗非发热性 CAUTI 的时间更长,而泌尿科医生则表示他们治疗发热性 CAUTI 的时间更长。此外,与泌尿科医生相比,全科医生使用氟喹诺酮类药物的比例更高,而泌尿科医生则更常使用预防性措施:结论:导管和 CAUTI 的处理给全科医生带来了很大的不确定性。全科医生和泌尿科医生对 CAUTI 的处理在治疗和预防方面存在明显差异。使用非推荐诊断方法和药物的情况很普遍。这种趋势以及不恰当的诊断方法和预防措施可能会增加抗菌素耐药性和 CAUTI 发病率。这项研究强调,有必要采取诊断和抗菌药物管理干预措施,并对全科医生和泌尿科医生进行 CAUTI 管理方面的适当培训。
{"title":"Exploring the real-world management of catheter-associated urinary tract infections by Swiss general practitioners and urologists: insights from an online survey.","authors":"Iris Zünti, Emilio Arbelaez, Sarah Tschudin-Sutter, Andreas Zeller, Florian S Halbeisen, Hans-Helge Seifert, Kathrin Bausch","doi":"10.57187/s.3933","DOIUrl":"https://doi.org/10.57187/s.3933","url":null,"abstract":"<p><strong>Aim: </strong>To assess and compare the real-world management of catheters and catheter-associated urinary tract infections (CAUTI) among Swiss general practitioners and urologists, encompassing diagnosis, treatment and prophylaxis.</p><p><strong>Methods: </strong>An anonymised online questionnaire was distributed among Swiss general practitioners and urologists between January and October 2023 via the networks of Sentinella and the Swiss Association of Urology. The questionnaire consisted of questions on catheter management, including diagnosis, treatment and prophylaxis of CAUTI. Analysis was performed by discipline. Fisher's exact test was applied for comparisons (statistical significance with p <0.05).</p><p><strong>Results: </strong>Out of 175 participating physicians, the majority were involved in catheter management. Urologists exhibited significantly higher levels of competence as compared to general practitioners (67.1% vs 20.9%). Although no significant differences were observed regarding diagnostic approaches between disciplines, unrecommended diagnostic methods were frequently applied. general practitioners reported that they treated non-febrile CAUTI for longer durations, while urologists indicated that they treated febrile CAUTI longer. Additionally, the use of fluoroquinolones was more prevalent among general practitioners compared to urologists, while prophylactic measures were more frequently applied by urologists.</p><p><strong>Conclusions: </strong>Catheter and CAUTI management entail significant uncertainty for general practitioners. CAUTI management varied notably between general practitioners and urologists in terms of treatment and prophylaxis. The use of non-recommended diagnostic approaches and drugs was common. This trend, along with inappropriate diagnostic methods and prophylaxis, may increase antimicrobial resistance and CAUTI morbidity. The study emphasises the necessity for diagnostic and antimicrobial stewardship interventions, and proper training in CAUTI management for general practitioners and urologists.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"154 ","pages":"3933"},"PeriodicalIF":2.1,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142628745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of electroconvulsive therapy response and remission in late-life depression: a review. 晚年抑郁症患者电休克疗法反应和缓解的预测:综述。
IF 2.1 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-05 DOI: 10.57187/s.3684
Beatriz Pozuelo Moyano, Kevin Swierkosz Lenart, Joëlle Rosselet Amoussou, Armin Von Gunten, Jean-Pierre Schuster

Electroconvulsive therapy is an effective and well-tolerated antidepressant treatment for the elderly population. The place of electroconvulsive therapy in the treatment sequence for depression in the elderly is currently not well established. This review aims to identify the factors that contribute to a positive response and remission in elderly patients with depression undergoing electroconvulsive therapy treatment. We searched five bibliographic databases (Medline ALL Ovid, Embase.com, APA PsycInfo Ovid, Cochrane Library Wiley and Web of Science Core Collection) for articles published between 1995 and June 2023. Of the 2149 articles screened, 19 were included in the review. No significant associations were found between remission and/or response and salivary cortisol, baseline hippocampal and white matter hyperintensities, total amyloid load or global cortical atrophy. The reviewed articles did not show a significant difference in remission between unilateral and bilateral electroconvulsive therapy treatment. Other interesting findings are that moderately elevated levels of CRP and S100B levels, lower retardation scores, poorer performance on the word reading task at baseline and longer post-ictal reorientation time may be associated with higher remission and/or response rates. Medial temporal atrophy can be associated with lower Montgomery-Åsberg Depression Rating Scale (MADRS) decrease after electroconvulsive therapy. Finally, elderly patients had higher rates of electroconvulsive therapy response; retardation and psychotic features may mediate this association. Incorporation of this data into clinical practice may facilitate a personalised approach to electroconvulsive therapy. However, research on this topic is scarce and there are few studies that focus specifically on older people.

电休克疗法是一种对老年人群有效且耐受性良好的抗抑郁治疗方法。目前,电休克疗法在老年抑郁症治疗序列中的地位尚未得到充分确定。本综述旨在找出有助于老年抑郁症患者在接受电休克疗法治疗后获得积极反应和缓解的因素。我们检索了五个文献数据库(Medline ALL Ovid、Embase.com、APA PsycInfo Ovid、Cochrane Library Wiley 和 Web of Science Core Collection)中 1995 年至 2023 年 6 月间发表的文章。在筛选出的 2149 篇文章中,有 19 篇被纳入综述。未发现缓解和/或反应与唾液皮质醇、基线海马和白质高密度、淀粉样蛋白总负荷或整体皮质萎缩之间存在明显关联。综述文章并未显示单侧和双侧电休克治疗在缓解方面存在显著差异。其他有趣的发现是,CRP和S100B水平中度升高、迟缓评分较低、基线时单词阅读任务表现较差以及发作后重新定向时间较长可能与较高的缓解率和/或反应率有关。颞叶内侧萎缩可能与电休克治疗后蒙哥马利-阿斯伯格抑郁量表(MADRS)降低有关。最后,老年患者的电休克治疗反应率较高;弱智和精神病特征可能是这一关联的中介因素。将这些数据纳入临床实践可能有助于电休克治疗的个性化方法。然而,这方面的研究还很少,而且专门针对老年人的研究也很少。
{"title":"Prediction of electroconvulsive therapy response and remission in late-life depression: a review.","authors":"Beatriz Pozuelo Moyano, Kevin Swierkosz Lenart, Joëlle Rosselet Amoussou, Armin Von Gunten, Jean-Pierre Schuster","doi":"10.57187/s.3684","DOIUrl":"https://doi.org/10.57187/s.3684","url":null,"abstract":"<p><p>Electroconvulsive therapy is an effective and well-tolerated antidepressant treatment for the elderly population. The place of electroconvulsive therapy in the treatment sequence for depression in the elderly is currently not well established. This review aims to identify the factors that contribute to a positive response and remission in elderly patients with depression undergoing electroconvulsive therapy treatment. We searched five bibliographic databases (Medline ALL Ovid, Embase.com, APA PsycInfo Ovid, Cochrane Library Wiley and Web of Science Core Collection) for articles published between 1995 and June 2023. Of the 2149 articles screened, 19 were included in the review. No significant associations were found between remission and/or response and salivary cortisol, baseline hippocampal and white matter hyperintensities, total amyloid load or global cortical atrophy. The reviewed articles did not show a significant difference in remission between unilateral and bilateral electroconvulsive therapy treatment. Other interesting findings are that moderately elevated levels of CRP and S100B levels, lower retardation scores, poorer performance on the word reading task at baseline and longer post-ictal reorientation time may be associated with higher remission and/or response rates. Medial temporal atrophy can be associated with lower Montgomery-Åsberg Depression Rating Scale (MADRS) decrease after electroconvulsive therapy. Finally, elderly patients had higher rates of electroconvulsive therapy response; retardation and psychotic features may mediate this association. Incorporation of this data into clinical practice may facilitate a personalised approach to electroconvulsive therapy. However, research on this topic is scarce and there are few studies that focus specifically on older people.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"154 ","pages":"3684"},"PeriodicalIF":2.1,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Supplementum 282: Abstracts Swiss Anaesthesia 2024, joint annual congress of the Swiss Society for Anaesthesiology and Perioperative Medicine and the Swiss Association for Anaesthesia Care. Supplementum 282:瑞士麻醉学和围术期医学会与瑞士麻醉护理协会联合年会 2024 年瑞士麻醉学摘要。
IF 2.1 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-04 DOI: 10.57187/s.4283
Swiss Society For Anaesthesiology And Perioperative Medicine, Swiss Association For Anaesthesia Care
{"title":"Supplementum 282: Abstracts Swiss Anaesthesia 2024, joint annual congress of the Swiss Society for Anaesthesiology and Perioperative Medicine and the Swiss Association for Anaesthesia Care.","authors":"Swiss Society For Anaesthesiology And Perioperative Medicine, Swiss Association For Anaesthesia Care","doi":"10.57187/s.4283","DOIUrl":"https://doi.org/10.57187/s.4283","url":null,"abstract":"","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"154 ","pages":"4283"},"PeriodicalIF":2.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142576030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Syphilis in pregnant women and congenital syphilis from 2012 to 2021 in Switzerland: a multicentre, retrospective study. 2012年至2021年瑞士孕妇梅毒和先天性梅毒:一项多中心回顾性研究。
IF 2.1 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-01 DOI: 10.57187/s.3678
Chloé Alberto, Noémie Wagner, Yves Fougère, Patrick M Meyer Sauteur, Gioia Scherler, Karoline Aebbi-Popp, Marc Baumann, Nina Schöbi, Gaud Catho, Stéphane Emonet, Christian Polli, Lisa Kottanattu, Christian Kahlert, David Baud, Alix Coste, Begoña Martinez De Tejada, Klara M Posfay Barbe, Laurence Toutous Trellu

Background and aims of the study: Congenital syphilis is a rare complication of syphilis in pregnant women. Vertical transmission may occur at any time during pregnancy. The incidence of congenital syphilis has been increasing worldwide. Congenital syphilis has been a notifiable disease for many years in Switzerland but reporting does not include maternal features associated with syphilis in pregnancy or infant's subsequent development. We described syphilis cases among pregnant women screened over a 10-year period in Switzerland and subsequent cases of congenital syphilis, in order to identify maternal risk profiles and to optimise prevention. Second, we compared the characteristics of pregnant women screened early (1st trimester) vs late in pregnancy (2nd or 3rd trimester). Finally, we assessed the risk factors for premature birth among these women with syphilis.

Methods: A multicentre retrospective study conducted in Swiss hospitals from 2012 to 2021, including pregnant women who screened positive for syphilis (Treponema pallidum haemagglutination assay [TPHA] / T. pallidum particle agglutination assay [TPPA ] ≥1:80) and newborns exposed to T. pallidum in utero and/or congenitally infected and with a positive syphilis serology at birth. Data were collected from medical records.

Results: A total of 147 syphilis-positive pregnant women and 102 infants were included. A history of treated syphilis was known for 44% (65/147) of the mothers corresponding to a serological scar and the remaining 56% (82/147) were newly identified syphilis cases. Syphilis screening was done during the first trimester in 54%, second trimester in 29% and third trimester in 13% of cases. Two babies were diagnosed with congenital syphilis (1.96%). Several potential factors that could contribute to women's risk of syphilis during pregnancy were identified such as a foreign origin (93% of mothers), lack of healthcare insurance (25%), no employment status (37%), drug use (5%), co-infection with other sexually transmitted infections (24%) and a late first antenatal consultation (42%). The number of pregnant women without insurance was higher in women diagnosed in the second or third trimester than in those diagnosed in the first trimester (odds ratio 0.41; 95% CI 0.19-0.89; p = 0.024). Syphilis diagnosed in the second or third trimester was associated with a late first antenatal consultation (odds ratio 77.82; 95% CI 9.81-617.21; p <0.001). A high rate of intrauterine growth retardation and of preterm birth was observed in newborns (18% versus 6% in Switzerland in 2022).

Conclusion: Congenital syphilis remains rare in Switzerland. However, we found potential maternal factors associated with a positive syphilis serology during pregnancy, which can help to improve future prevention measures. The study protocol was registered on ClinicalTrials.gov (ID NCT05975502).

研究的背景和目的:先天性梅毒是孕妇梅毒的一种罕见并发症。垂直传播可能发生在怀孕期间的任何时候。先天性梅毒的发病率在全球范围内呈上升趋势。在瑞士,先天性梅毒多年来一直是一种应报告的疾病,但报告并不包括与妊娠期梅毒或婴儿后续发育相关的母体特征。我们描述了瑞士10年间接受筛查的孕妇中的梅毒病例以及随后出现的先天性梅毒病例,以确定孕产妇的风险特征,优化预防措施。其次,我们比较了孕早期(怀孕前三个月)和孕晚期(怀孕后三个月或三个月)接受筛查的孕妇的特征。最后,我们评估了这些梅毒孕妇早产的风险因素:方法:2012年至2021年在瑞士医院开展的一项多中心回顾性研究,包括梅毒筛查阳性(苍白螺旋体血凝试验[TPHA] /苍白螺旋体颗粒凝集试验[TPPA] ≥1:80)的孕妇和在子宫内暴露于苍白螺旋体和/或先天感染梅毒且出生时梅毒血清学检测呈阳性的新生儿。数据来自医疗记录:结果:共纳入147名梅毒阳性孕妇和102名婴儿。44%(65/147)的母亲有梅毒治疗史,血清学疤痕阳性,其余56%(82/147)为新发现的梅毒病例。54%的梅毒筛查是在妊娠头三个月进行的,29%是在妊娠后三个月进行的,13%是在妊娠后三个月进行的。两名婴儿被诊断患有先天性梅毒(1.96%)。研究发现了几种可能导致妇女在怀孕期间感染梅毒的潜在因素,如来自国外(93%的母亲)、没有医疗保险(25%)、没有工作(37%)、吸毒(5%)、合并感染其他性传播疾病(24%)和首次产前咨询过晚(42%)。与妊娠头三个月的孕妇相比,妊娠后三个月或第三个月确诊的孕妇中没有保险的人数更高(几率比 0.41;95% CI 0.19-0.89;P = 0.024)。第二或第三孕期确诊的梅毒与首次产前咨询时间较晚有关(几率比77.82;95% CI 9.81-617.21;P 结论:先天性梅毒仍然很少见:先天性梅毒在瑞士仍然很少见。不过,我们发现了与孕期梅毒血清学阳性相关的潜在母体因素,这有助于改进未来的预防措施。研究方案已在ClinicalTrials.gov(ID NCT05975502)上注册。
{"title":"Syphilis in pregnant women and congenital syphilis from 2012 to 2021 in Switzerland: a multicentre, retrospective study.","authors":"Chloé Alberto, Noémie Wagner, Yves Fougère, Patrick M Meyer Sauteur, Gioia Scherler, Karoline Aebbi-Popp, Marc Baumann, Nina Schöbi, Gaud Catho, Stéphane Emonet, Christian Polli, Lisa Kottanattu, Christian Kahlert, David Baud, Alix Coste, Begoña Martinez De Tejada, Klara M Posfay Barbe, Laurence Toutous Trellu","doi":"10.57187/s.3678","DOIUrl":"https://doi.org/10.57187/s.3678","url":null,"abstract":"<p><strong>Background and aims of the study: </strong>Congenital syphilis is a rare complication of syphilis in pregnant women. Vertical transmission may occur at any time during pregnancy. The incidence of congenital syphilis has been increasing worldwide. Congenital syphilis has been a notifiable disease for many years in Switzerland but reporting does not include maternal features associated with syphilis in pregnancy or infant's subsequent development. We described syphilis cases among pregnant women screened over a 10-year period in Switzerland and subsequent cases of congenital syphilis, in order to identify maternal risk profiles and to optimise prevention. Second, we compared the characteristics of pregnant women screened early (1st trimester) vs late in pregnancy (2nd or 3rd trimester). Finally, we assessed the risk factors for premature birth among these women with syphilis.</p><p><strong>Methods: </strong>A multicentre retrospective study conducted in Swiss hospitals from 2012 to 2021, including pregnant women who screened positive for syphilis (Treponema pallidum haemagglutination assay [TPHA] / T. pallidum particle agglutination assay [TPPA ] ≥1:80) and newborns exposed to T. pallidum in utero and/or congenitally infected and with a positive syphilis serology at birth. Data were collected from medical records.</p><p><strong>Results: </strong>A total of 147 syphilis-positive pregnant women and 102 infants were included. A history of treated syphilis was known for 44% (65/147) of the mothers corresponding to a serological scar and the remaining 56% (82/147) were newly identified syphilis cases. Syphilis screening was done during the first trimester in 54%, second trimester in 29% and third trimester in 13% of cases. Two babies were diagnosed with congenital syphilis (1.96%). Several potential factors that could contribute to women's risk of syphilis during pregnancy were identified such as a foreign origin (93% of mothers), lack of healthcare insurance (25%), no employment status (37%), drug use (5%), co-infection with other sexually transmitted infections (24%) and a late first antenatal consultation (42%). The number of pregnant women without insurance was higher in women diagnosed in the second or third trimester than in those diagnosed in the first trimester (odds ratio 0.41; 95% CI 0.19-0.89; p = 0.024). Syphilis diagnosed in the second or third trimester was associated with a late first antenatal consultation (odds ratio 77.82; 95% CI 9.81-617.21; p <0.001). A high rate of intrauterine growth retardation and of preterm birth was observed in newborns (18% versus 6% in Switzerland in 2022).</p><p><strong>Conclusion: </strong>Congenital syphilis remains rare in Switzerland. However, we found potential maternal factors associated with a positive syphilis serology during pregnancy, which can help to improve future prevention measures. The study protocol was registered on ClinicalTrials.gov (ID NCT05975502).</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"154 ","pages":"3678"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severity of native pulmonary annular hypoplasia and late outcomes of tetralogy of Fallot: retrospective cohort study. 原发性肺动脉环发育不全的严重程度与法洛氏四联症的晚期预后:回顾性队列研究。
IF 2.1 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-01 DOI: 10.57187/s.3689
Tugba Erdil, Klaus Steigmiller, John Ethan Rampa, Martin Christmann, Ulrike Held, Hitendu Dave
<p><strong>Objective: </strong>Pulmonary annular hypoplasia and valvar dysplasia are key morphological features affecting long-term outcomes of tetralogy of Fallot. This retrospective study aimed to analyse factors affecting contemporary long-term outcomes with a focus on pulmonary annular growth and function over time.</p><p><strong>Methods: </strong>131 consecutive isolated tetralogy of Fallot repairs performed between 2004 and 2014 at University Children's Hospital Zurich were included. Median age and weight at the time of repair were 4.8 (interquartile range [IQR] 3.2-6.3) months and 6.1 (IQR 5.1-7) kg, respectively. Based on the severity of native pulmonary annular hypoplasia, the cohort was divided into group 1 (preoperative pulmonary annular Z score < -4; n = 20), group 2 (Z score -2 to -4; n = 56) and group 3 (Z score > -2; n = 54). A transannular patch was used in 88/131 (67.2%) patients: 80%, 67.9% and 61.1% in groups 1, 2 and 3, respectively. The primary outcome was defined as right ventricular outflow tract (RVOT) reoperation or pulmonary valve replacement. Secondary outcome was composite pulmonary valve dysfunction defined as peak gradient >40 mm Hg or severe pulmonary regurgitation at follow-up. A multiple Cox regression model was used to quantify the association of age at tetralogy of Fallot repair, preoperative pulmonary annular Z score and RVOT approach with primary and secondary outcome. Follow-up was 98.5% complete, with a median follow-up duration of 9.6 (95% confidence interval [CI] 9-10.4) years.</p><p><strong>Results: </strong>All patients were alive at last follow-up resulting in 100% survival. 20/131 patients underwent pulmonary valve replacement (14 surgical and 6 catheter interventional) while 5/131 underwent RVOT reoperations other than valve replacement. The Kaplan-Meier 10-year freedom from primary outcome was 85% (95% CI 78-92%); 69% (46-100%), 91% (82-100%) and 84% (74-95%) for groups 1, 2 and 3, respectively (log rank p = 0.16). Composite dysfunction at follow-up was observed in 29.8% (overall): 45%, 28.6% and 25.9% for groups 1, 2 and 3, respectively (p = 0.12). The multiple Cox regression analysis for primary outcome indicated that the use of a transannular patch results in a Hazard Ratio (HR) of 3.3 (95% CI 0.7-14.7, p = 0.13). Additionally, the presence of composite dysfunction at discharge results in a HR of 2.1 (95% CI 0.8-5.4, p = 0.1). Age (in months) with a HR of 0.8 (95% CI 0.6-1, p = 0.06) and group 2 with a HR of 0.4 (95% CI 0.14-1.2, p = 0.11) showed a trend to being protective for the primary outcome. However, the 95% CI of all estimates included the HR of 1.</p><p><strong>Conclusions: </strong>Transannular patch use and composite dysfunction at discharge, although not statistically significant at 5% level, may be associated with pulmonary valve replacement and RVOT reoperation. Avoiding the use of a transannular patch or using reconstructive techniques to achieve a better composite dysfunction at di
目的:肺动脉环发育不良和瓣膜发育不良是影响法洛氏四联症长期预后的主要形态特征。这项回顾性研究旨在分析影响当代长期预后的因素,重点关注肺动脉环随着时间推移的生长和功能。方法:研究纳入了 2004 年至 2014 年期间在苏黎世大学儿童医院进行的 131 例连续孤立法洛四联症修复手术。修复手术时的中位年龄和体重分别为4.8个月(四分位距[IQR] 3.2-6.3)和6.1(IQR 5.1-7)公斤。根据原发性肺动脉瓣环发育不全的严重程度,队列被分为第1组(术前肺动脉瓣环Z评分<-4;n=20)、第2组(Z评分-2至-4;n=56)和第3组(Z评分>-2;n=54)。88/131(67.2%)例患者使用了经腔补片:第 1、2 和 3 组的使用率分别为 80%、67.9% 和 61.1%。主要结果定义为右室流出道(RVOT)再手术或肺动脉瓣置换术。次要结果是复合肺动脉瓣功能障碍,即随访时峰值梯度>40毫米汞柱或严重肺动脉瓣反流。采用多元 Cox 回归模型来量化法洛四联症修复时的年龄、术前肺动脉瓣环 Z 评分和 RVOT 方法与主要和次要结果的关系。随访完成率为 98.5%,中位随访时间为 9.6 年(95% 置信区间 [CI] 9-10.4 年):结果:所有患者在最后一次随访时均存活,存活率为 100%。20/131例患者接受了肺动脉瓣置换术(14例手术,6例导管介入),5/131例患者接受了除瓣膜置换术以外的RVOT再手术。第 1、2 和 3 组的主要结局 10 年 Kaplan-Meier 自由度分别为 85% (95% CI 78-92%)、69% (46-100%)、91% (82-100%) 和 84% (74-95%)(对数秩 p = 0.16)。29.8% 的患者(总体)在随访时出现综合功能障碍:1、2、3 组分别为 45%、28.6% 和 25.9%(P = 0.12)。针对主要结果的多重考克斯回归分析表明,使用经环形补片的危险比(HR)为 3.3(95% CI 0.7-14.7,P = 0.13)。此外,出院时出现复合功能障碍的危险比为 2.1 (95% CI 0.8-5.4, p = 0.1)。年龄(以月为单位)的 HR 为 0.8(95% CI 0.6-1,p = 0.06),第 2 组的 HR 为 0.4(95% CI 0.14-1.2,p = 0.11),显示出对主要结果有保护作用的趋势。然而,所有估计值的 95% CI 均包括 HR 1.结论:结论:经瓣膜贴片的使用和出院时的综合功能障碍虽然在 5%水平上无统计学意义,但可能与肺动脉瓣置换术和 RVOT 再次手术有关。避免使用跨瓣补片或使用重建技术来改善出院时的综合功能障碍,可降低主要结局。需要进行大型多中心研究,以更准确地证明肺动脉瓣环 Z 评分对预后的影响。
{"title":"Severity of native pulmonary annular hypoplasia and late outcomes of tetralogy of Fallot: retrospective cohort study.","authors":"Tugba Erdil, Klaus Steigmiller, John Ethan Rampa, Martin Christmann, Ulrike Held, Hitendu Dave","doi":"10.57187/s.3689","DOIUrl":"https://doi.org/10.57187/s.3689","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Pulmonary annular hypoplasia and valvar dysplasia are key morphological features affecting long-term outcomes of tetralogy of Fallot. This retrospective study aimed to analyse factors affecting contemporary long-term outcomes with a focus on pulmonary annular growth and function over time.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;131 consecutive isolated tetralogy of Fallot repairs performed between 2004 and 2014 at University Children's Hospital Zurich were included. Median age and weight at the time of repair were 4.8 (interquartile range [IQR] 3.2-6.3) months and 6.1 (IQR 5.1-7) kg, respectively. Based on the severity of native pulmonary annular hypoplasia, the cohort was divided into group 1 (preoperative pulmonary annular Z score &lt; -4; n = 20), group 2 (Z score -2 to -4; n = 56) and group 3 (Z score &gt; -2; n = 54). A transannular patch was used in 88/131 (67.2%) patients: 80%, 67.9% and 61.1% in groups 1, 2 and 3, respectively. The primary outcome was defined as right ventricular outflow tract (RVOT) reoperation or pulmonary valve replacement. Secondary outcome was composite pulmonary valve dysfunction defined as peak gradient &gt;40 mm Hg or severe pulmonary regurgitation at follow-up. A multiple Cox regression model was used to quantify the association of age at tetralogy of Fallot repair, preoperative pulmonary annular Z score and RVOT approach with primary and secondary outcome. Follow-up was 98.5% complete, with a median follow-up duration of 9.6 (95% confidence interval [CI] 9-10.4) years.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;All patients were alive at last follow-up resulting in 100% survival. 20/131 patients underwent pulmonary valve replacement (14 surgical and 6 catheter interventional) while 5/131 underwent RVOT reoperations other than valve replacement. The Kaplan-Meier 10-year freedom from primary outcome was 85% (95% CI 78-92%); 69% (46-100%), 91% (82-100%) and 84% (74-95%) for groups 1, 2 and 3, respectively (log rank p = 0.16). Composite dysfunction at follow-up was observed in 29.8% (overall): 45%, 28.6% and 25.9% for groups 1, 2 and 3, respectively (p = 0.12). The multiple Cox regression analysis for primary outcome indicated that the use of a transannular patch results in a Hazard Ratio (HR) of 3.3 (95% CI 0.7-14.7, p = 0.13). Additionally, the presence of composite dysfunction at discharge results in a HR of 2.1 (95% CI 0.8-5.4, p = 0.1). Age (in months) with a HR of 0.8 (95% CI 0.6-1, p = 0.06) and group 2 with a HR of 0.4 (95% CI 0.14-1.2, p = 0.11) showed a trend to being protective for the primary outcome. However, the 95% CI of all estimates included the HR of 1.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Transannular patch use and composite dysfunction at discharge, although not statistically significant at 5% level, may be associated with pulmonary valve replacement and RVOT reoperation. Avoiding the use of a transannular patch or using reconstructive techniques to achieve a better composite dysfunction at di","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"154 ","pages":"3689"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antipsychotic, benzodiazepine and Z-drug prescriptions in a Swiss hospital network in the Choosing Wisely and COVID-19 eras: a longitudinal study. 瑞士一家医院网络在 "明智选择 "和 "COVID-19 "时代的抗精神病药、苯二氮卓类药物和 Z 类药物处方:一项纵向研究。
IF 2.1 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-11-01 DOI: 10.57187/s.3409
Vanessa Gagliano, Gloria Salemme, Alessandro Ceschi, Angela Greco, Nicola Grignoli, Luca Clivio, Alessandro Merler, Vanessa Feyling Benitez, Jvan Gianini, Martina Zandonà, Luca Gabutti
<p><strong>Aims of the study: </strong>Physicians frequently prescribe antipsychotics off-label to treat, among others, insomnia and anxiety. The Swiss "smarter medicine - Choosing Wisely" campaign has tried to raise awareness about the risks and to limit benzodiazepine and Z-drug prescriptions. In the Italian-speaking part of Switzerland, our network of public hospitals joined the campaign with the aim of avoiding unnecessary benzodiazepine and Z-drug treatments, with prescription monitoring, benchmarking and educational contributions. Considering the risks of a possible shift towards the prescription of antipsychotics, and aware of the potential role of the COVID-19 pandemic, we decided to analyse the prescription trends of antipsychotics and benzodiazepines/Z-drugs before, during (2016-2017) and after the intervention.</p><p><strong>Methods: </strong>For this longitudinal study, we reactivated a continuous monitoring of inpatient benzodiazepine/Z-drug and antipsychotics prescriptions/deprescriptions, paused in 2018 after the end of the internal Choosing Wisely campaign, based on routinely collected observational health data. We screened all demographic, administrative and prescription data of patients admitted to the internal medicine department of the four teaching hospitals (H1-H4) belonging to the EOC (Ente Ospedaliero Cantonale) network, from the fourth quarter of 2014 to the second quarter of 2023.</p><p><strong>Results: </strong>We analysed 74,659 hospital stays (14,645 / 16,083 / 24,285 / 19,646 at hospitals H1 / H2 / H3 / H4 respectively). The mean (± SD) case mix (a metric that reflects the diversity, complexity and severity of the treated patients) and patient age were 1.08 ± 0.14 and 73 ± 2 years. 10.6% and 12.1% of patients received antipsychotics prior to admission and at discharge respectively (new prescriptions 3.3 ± 0.7%; deprescriptions 13.3 ± 5.2%). New prescriptions showed an upward trend, with +0.20% per year (p <0.001). Patients admitted with ongoing antipsychotics therapy increased 0.36% per year (p <0.001). New benzodiazepine/Z-drug prescriptions showed a 0.20% per year decrease (p = 0.01). Patients admitted with ongoing benzodiazepine/Z-drug therapy decreased 0.32% per year (p <0.001). New antipsychotics prescriptions showed differences between hospitals, with H3 above and H2 below the average.</p><p><strong>Conclusions: </strong>The increase in antipsychotics quantitatively matched the decrease in benzodiazepine/Z-drug prescribing, suggesting a shift from one to the other sedative therapy. The same trend was visible in the ongoing prescriptions at admission revealing a similar out-of-hospital approach. This suggests a change in sedative prescribing strategy rather than the choice of alternative, non-pharmacological approaches. Furthermore, the variation between similar services of different hospitals points out the consequences of local prescribing cultures and the importance of continuously monitoring and benchmarking
研究目的医生经常在标签外开具抗精神病药物处方,用于治疗失眠和焦虑等症状。瑞士的 "明智用药-明智选择 "运动试图提高人们对其风险的认识,并限制苯二氮卓类药物和 Z 类药物的处方。在瑞士的意大利语地区,我们的公立医院网络也加入了这一运动,目的是通过处方监测、基准设定和教育贡献,避免不必要的苯二氮卓和 Z 类药物治疗。考虑到抗精神病药物处方可能发生转变的风险,并意识到 COVID-19 大流行的潜在作用,我们决定分析干预前、干预期间(2016-2017 年)和干预后抗精神病药物和苯二氮卓/Z 类药物的处方趋势:在这项纵向研究中,我们重新启动了对住院患者苯二氮卓/Z-类药物和抗精神病药物处方/处方的持续监测,在内部 "明智选择 "运动结束后的2018年暂停了这项工作,并以常规收集的观察性健康数据为基础。我们筛选了属于 EOC(Ente Ospedaliero Cantonale)网络的四家教学医院(H1-H4)内科住院患者的所有人口统计学、行政管理和处方数据,时间从 2014 年第四季度到 2023 年第二季度:我们分析了 74,659 次住院(H1/H2/H3/H4 医院分别为 14,645 次/16,083 次/24,285 次/19,646 次)。平均(± SD)病例组合(反映治疗患者的多样性、复杂性和严重性的指标)和患者年龄分别为 1.08 ± 0.14 岁和 73 ± 2 岁。10.6%和12.1%的患者在入院前和出院时分别服用了抗精神病药物(新处方3.3±0.7%;停药13.3±5.2%)。新处方呈上升趋势,每年增加 0.20%(p 结论:新处方的增加与抗精神病药物的增加有关:抗精神病药物处方量的增加与苯二氮卓/Z 类药物处方量的减少相吻合,这表明镇静剂疗法正在从一种向另一种转变。入院时的持续处方也呈现出同样的趋势,显示出类似的院外治疗方法。这表明镇静剂处方策略发生了变化,而不是选择了其他非药物疗法。此外,不同医院同类服务之间的差异也说明了当地处方文化的影响,以及持续监控和设定用药处方基准的重要性。
{"title":"Antipsychotic, benzodiazepine and Z-drug prescriptions in a Swiss hospital network in the Choosing Wisely and COVID-19 eras: a longitudinal study.","authors":"Vanessa Gagliano, Gloria Salemme, Alessandro Ceschi, Angela Greco, Nicola Grignoli, Luca Clivio, Alessandro Merler, Vanessa Feyling Benitez, Jvan Gianini, Martina Zandonà, Luca Gabutti","doi":"10.57187/s.3409","DOIUrl":"https://doi.org/10.57187/s.3409","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Aims of the study: &lt;/strong&gt;Physicians frequently prescribe antipsychotics off-label to treat, among others, insomnia and anxiety. The Swiss \"smarter medicine - Choosing Wisely\" campaign has tried to raise awareness about the risks and to limit benzodiazepine and Z-drug prescriptions. In the Italian-speaking part of Switzerland, our network of public hospitals joined the campaign with the aim of avoiding unnecessary benzodiazepine and Z-drug treatments, with prescription monitoring, benchmarking and educational contributions. Considering the risks of a possible shift towards the prescription of antipsychotics, and aware of the potential role of the COVID-19 pandemic, we decided to analyse the prescription trends of antipsychotics and benzodiazepines/Z-drugs before, during (2016-2017) and after the intervention.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;For this longitudinal study, we reactivated a continuous monitoring of inpatient benzodiazepine/Z-drug and antipsychotics prescriptions/deprescriptions, paused in 2018 after the end of the internal Choosing Wisely campaign, based on routinely collected observational health data. We screened all demographic, administrative and prescription data of patients admitted to the internal medicine department of the four teaching hospitals (H1-H4) belonging to the EOC (Ente Ospedaliero Cantonale) network, from the fourth quarter of 2014 to the second quarter of 2023.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;We analysed 74,659 hospital stays (14,645 / 16,083 / 24,285 / 19,646 at hospitals H1 / H2 / H3 / H4 respectively). The mean (± SD) case mix (a metric that reflects the diversity, complexity and severity of the treated patients) and patient age were 1.08 ± 0.14 and 73 ± 2 years. 10.6% and 12.1% of patients received antipsychotics prior to admission and at discharge respectively (new prescriptions 3.3 ± 0.7%; deprescriptions 13.3 ± 5.2%). New prescriptions showed an upward trend, with +0.20% per year (p &lt;0.001). Patients admitted with ongoing antipsychotics therapy increased 0.36% per year (p &lt;0.001). New benzodiazepine/Z-drug prescriptions showed a 0.20% per year decrease (p = 0.01). Patients admitted with ongoing benzodiazepine/Z-drug therapy decreased 0.32% per year (p &lt;0.001). New antipsychotics prescriptions showed differences between hospitals, with H3 above and H2 below the average.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The increase in antipsychotics quantitatively matched the decrease in benzodiazepine/Z-drug prescribing, suggesting a shift from one to the other sedative therapy. The same trend was visible in the ongoing prescriptions at admission revealing a similar out-of-hospital approach. This suggests a change in sedative prescribing strategy rather than the choice of alternative, non-pharmacological approaches. Furthermore, the variation between similar services of different hospitals points out the consequences of local prescribing cultures and the importance of continuously monitoring and benchmarking","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"154 ","pages":"3409"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Swiss medical weekly
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1